Dennis M. Black,Pierre D. Delmas,Richard Eastell,Ian R. Reid,Steven Boonen,Jane A. Cauley,Felicia Cosman,Péter Lakatos,Ping Chung Leung,Z. Man,C. Mautalén,Peter Mesenbrink,Huilin Hu,John Caminis,Karen Tong,Theresa Rosario-Jansen,Joel Krasnow,Trisha F. Hue,Deborah E. Sellmeyer,Erik Fink Eriksen,Steven R. Cummings
A single infusion of intravenous zoledronic acid decreases bone turnover and improves bone density at 12 months in postmenopausal women with osteoporosis. We assessed the effects of annual infusions of zoledronic acid on fracture risk during a 3-year period.